Course Information

Release date: August 26, 2026
Expiration date: November 26, 2026
Estimated time to complete activity: 15 minutes

PROVIDER STATEMENT

This activity is provided by Integrity CE, LLC.

DISCLOSURE OF COMMERCIAL SUPPORT

This activity is supported by an educational grant from AstraZeneca Pharmaceuticals.
This activity is supported by an independent medical educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

PROGRAM OVERVIEW

This enduring activity follows a patient with recurrent epidermal growth factor receptor (EGFR) exon 19 deletion-positive non-small cell lung cancer (NSCLC) who achieves more than 4 years of disease control with osimertinib before developing a single enlarging pulmonary lesion. The case is designed around key clinical decisions in NSCLC care, such as whether the new lesion represents failure of osimertinib as a whole, escape by one resistant clone, occult histologic transformation, or the beginning of broader systemic progression. The discussion integrates paired tissue and plasma assessment, central nervous system (CNS) restaging, local ablative therapy with continued EGFR inhibition, post-osimertinib systemic options, frontline intensification, and strategies for proactive toxicity management with next-line therapy.

Learning Objectives

TARGET AUDIENCE

This activity addresses the needs of medical, surgical, and radiation oncologists, pulmonologists, physician assistants, nurse practitioners, nurses, and other healthcare providers involved in the treatment and management of patients with lung cancer.

LEARNING OBJECTIVES

Upon completion of this educational activity, participants should be able to:

Evaluate roles for precision medicine assessments to guide prognostic evaluation and therapeutic decision-making in lung cancer
Recognize personalized therapeutic decisions consistent with evidence-based practices in lung cancer
Monitor for and manage potential unique toxicities associated with recently approved and emerging therapies for lung cancer

Faculty Information and Disclosures

FACULTY

Deborah Doroshow, MD, PhD

Associate Professor

Hematology and Medical Oncology

Director of Targeted Therapies, Mount Sinai Early Phase Trials Unit

Icahn School of Medicine

Mount Sinai Hospital

New York, New York

Noah Osei, MBChB

Hematology and Medical Oncology Fellow

Icahn School of Medicine

Mount Sinai Hospital

New York, New York

DISCLOSURE OF CONFLICTS OF INTEREST

Integrity CE, LLC requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any financial relationships with ineligible companies. All identified relevant financial relationships are thoroughly vetted by Integrity CE, LLC for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated. The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CME activity:

Deborah Doroshow, MD, PhD

Advisory Boards: AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Johnson and Johnson, Lilly, Natera, Nuvation, Pfizer, Summit

Noah Osei, MBChB does not have any financial relationships or relationships to products or devices with ineligible companies.

The Integrity CE, LLC planners and managers do not have any financial relationships or relationships to products or devices with ineligible companies.

Accreditation Information

DIRECTIONS TO LEARNER

There are no fees for participating and receiving CME credit for this activity. During the period of August 26, 2026, 2026 through November 26, 2026, participants must:

Read the learning objectives
Complete the pretest
Study the educational activity
Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed posttest with a score of 33% or better and a completed activity evaluation form.

ACCREDITATION STATEMENT

Integrity CE, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION

Integrity CE, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CONTACT INFORMATION

For information about ACCME accreditation of this activity, please contact Integrity CE, LLC at (855) 835-4004 or cme@integrityce.com.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity CE, LLC does not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimers and Technical Requirements

MEDIA

Internet

PRIVACY POLICY

When you participate in an online educational activity sponsored by Integrity CE, LLC, you will be asked for your name, degree(s), affiliation(s), street address, telephone number and…(continued)

MINIMUM SYSTEM REQUIREMENTS

Internet: Stable connection
Operating Systems: Windows 10/macOS 10.14 or later recommended
Web Browser: Latest versions of Google Chrome, Microsoft Edge, or Safari recommended (other modern browsers also supported)
Plug-ins: No plug-ins required

For optimal performance and security, ensure your browser is up to date and avoid using unsupported or outdated versions.

DISCLAIMER

The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Release date: August 26, 2026Expiration date: November 26, 2026 Estimated time to complete activity: 15 minutes

Resistance, Recurrence, and Reassessment: A Tumor Board Approach to EGFR-Mutant NSCLC